Osaka, Japan

Katsuji Aikawa

USPTO Granted Patents = 6 


 

Average Co-Inventor Count = 5.5

ph-index = 4

Forward Citations = 24(Granted Patents)


Location History:

  • Takatsuki, JP (2008 - 2013)
  • Osaka, JP (2007 - 2018)

Company Filing History:


Years Active: 2007-2018

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Katsuji Aikawa: Innovator in Cyclic Compounds

Introduction

Katsuji Aikawa is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of cyclic compounds, particularly in the development of compounds with CCR antagonist activity. His work has led to the filing of six patents, showcasing his innovative approach to chemical research.

Latest Patents

One of Katsuji Aikawa's latest patents is focused on a bicyclic compound that exhibits CCR antagonist activity, specifically targeting CCR5. The invention provides a new cyclic compound represented by a specific formula, which includes various ring groups and bivalent structures. This compound has potential applications in therapeutic settings, particularly in the treatment of diseases related to CCR5 activity.

Career Highlights

Throughout his career, Katsuji Aikawa has worked with notable companies in the pharmaceutical industry, including Tobira Therapeutics, Inc. and Takeda Pharmaceutical Company Limited. His experience in these organizations has allowed him to collaborate on groundbreaking research and development projects.

Collaborations

Katsuji Aikawa has collaborated with esteemed colleagues such as Mitsuru Shiraishi and Masanori Baba. These partnerships have contributed to the advancement of his research and the successful development of innovative compounds.

Conclusion

Katsuji Aikawa's contributions to the field of cyclic compounds and his innovative patents highlight his role as a leading inventor in the pharmaceutical industry. His work continues to influence research and development in therapeutic applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…